Muscle News and Research

RSS

Toronto at forefront of stem cell technology

A $20-million deal announced to license Canadian stem cell technology in the U.S. underscores the Toronto area's global leadership in stem cell research.

23 Jun 2007

Scientists identify gene responsible for one type of Charcot-Marie-Tooth disorder

Scientists have identified the gene responsible for one type of Charcot-Marie-Tooth disorder, a common inherited neurological disease, thanks to the chance appearance of a strain of impaired 'pale tremor' mice in a University of Michigan research laboratory.

23 Jun 2007

U.S. FDA approves Lyrica (pregabalin), the first drug to treat fibromyalgia

The U.S. Food and Drug Administration has approved Lyrica (pregabalin), the first drug to treat fibromyalgia, a disorder characterized by pain, fatigue and sleep problems.

23 Jun 2007

Kidney specialists review plans for disaster response

Hurricane Katrina and other recent disasters have focused attention on the urgent need for planning to provide health services after natural disasters.

23 Jun 2007

Stem cells to repair damaged heart muscle

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

22 Jun 2007

Why excessive body weight increases the risk for heart disease

New research from The University of Arizona Sarver Heart Center helps explain why excessive body weight increases the risk for heart disease.

20 Jun 2007

Differences in sleep patterns

Researchers have long observed significant differences in normal people's sleep. Some are light sleepers, whereas others sleep deeply.

20 Jun 2007

Coffee protects against involuntary eye spasm

People who drink coffee are less likely to develop an involuntary eye spasm called primary late onset blepharospasm, which makes them blink uncontrollably and can leave them effectively ‘blind', according to a study published online ahead of print in the Journal of Neurology Neurosurgery and Psychiatry .

20 Jun 2007

Researchers develop artificial blood vessels from muscle-derived stem cells and a biodegradable polymer

University of Pittsburgh School of Medicine investigators have engineered artificial blood vessels from muscle-derived stem cells (MDSCs) and a biodegradable polymer that exhibit extensive remodeling and remain free of blockages when grafted into rats.

19 Jun 2007

New target for therapies for retinopathy

A protein long thought to be one of the body's supporting players has quietly been taking a lead role in healthy eyesight, a discovery that could rapidly lead to treatments for babies born before their eyes are finished growing, University of Florida and Harvard Medical School researchers have found.

19 Jun 2007

Common DNA variations underlie susceptibility to fever after smallpox vaccination

Their finding is the first to link individual differences written into the genetic code with a vaccine-related complication, albeit a mild one.

19 Jun 2007

Fat oxidation during exercise and physical activity

In a paper published in The Journal of Physiology, Helge, Stallknecht, Richter, Galbo, and Keins from Copenhagen shed light on fat oxidation during exercise and physical activity.

19 Jun 2007

Novel mutation associated with muscle identified

The study demonstrates that muscle weakness experienced by persons with a regulatory protein tropomyosin mutation is directly related to a mechanism by which the mutant tropomyosin modulates contractile speed and force-generation capacity.

17 Jun 2007

Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis

Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced the presentation of additional data that showed that the safety profile of Enbrel, (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy.

17 Jun 2007

Solvay Pharmaceuticals submits supplemental NDA for AndroGel

Solvay Pharmaceuticals, Inc., has announced that it submitted a supplemental New Drug Application (sNDA) for AndroGel (testosterone gel) 1% CIII to the U.S. Food and Drug Administration (FDA) for treatment in male adolescents ages 13-17 years old with primary or secondary hypogonadism.

17 Jun 2007

Diagnosing cancer at early stages imperative for survival

Early detection of cancer through regular screenings can greatly increase survival rates because it identifies cancer when it's most treatable, according to the National Cancer Institute.

17 Jun 2007

Newer breast cancer drug may protect heart

By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

16 Jun 2007

Structure of protein altered in autism revealed

As a result of mapping the structure of the protein complex implicated in autism spectrum disorders, a research team led by scientists at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences has discovered how particular genetic mutations affect this complex and contribute to the developmental abnormalities found in children with autism.

15 Jun 2007

Interfacing silicon nanowires with mammalian cells

A research team at the University of California, Berkeley, has achieved a significant step toward one of the futuristic goals of nanomedicine and nanobiology-developing technology for "wiring" together individual cells.

14 Jun 2007

New target for Type 2 diabetes

Researchers at the University of Pennsylvania School of Medicine have discovered a potential new target for treating type 2 diabetes, according to a new study that appeared online this week in Nature.

14 Jun 2007